Drug news
NICE does not recommend Imbruvica (ibrutinib) to treat chronic lymphocytic leukaemia- Janssen
The National Institute for Health and Care Excellence (NICE) has not recommended Imbruvica (ibrutinib) from Janssen Pharma for the treatment of chronic lymphocytic leukaemia on the grounds that it is not cost effective. The company had offered a patient access scheme to the Department of Health and provided a discounted price.